DexCom (DXCM) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
10x Genomics (TXG) has outperformed DexCom (DXCM) over the past year, gaining 540.3% versus a gain of 24.5%. Over five years, DXCM leads with a -38.0% price change compared with -49.2% for TXG. DexCom is the larger company by market cap ($31.85 billion vs $10.07 billion), about 3.2 times the size.
On valuation, DexCom trades at a lower forward P/E (27.0x vs 1008.0x for 10x Genomics). DexCom converts more of its revenue into profit, with a net margin of 17.9% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | TXG |
|---|---|---|
| Share price | $84.41 | $77.28 |
| Market cap | $31.85B | $10.07B |
| 1-day change | +0.13% | +1.55% |
| YTD return | +27.18% | +373.82% |
| 1-year return | +24.54% | +540.27% |
| 5-year return | -37.99% | -49.25% |
| P/E ratio (TTM) | 33.50 | — |
| Forward P/E | 26.99 | — |
| EPS (TTM) | $2.52 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.66B | $642.82M |
| Revenue growth (YoY) | +15.60% | +5.25% |
| Net income (latest FY) | $836.30M | $-43.54M |
| Gross margin | 60.10% | 69.05% |
| Operating margin | 19.56% | -9.49% |
| Net margin | 17.94% | -6.77% |
| 52-week high | $92.59 | $102.81 |
| 52-week low | $54.11 | $11.16 |
| Distance from 52-week high | -8.83% | -24.83% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.00% | -12.69% |
| Average volume | 4.43M | 3.29M |
| Shares outstanding | 377.36M | 120.21M |
| Employees | 11,000 | 1,178 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DexCom is about 3.2 times larger than 10x Genomics by market value ($31.85B vs $10.07B).
- TXG has outperformed DXCM by 515.7 percentage points over the past year.
- DexCom is more profitable, keeping 17.9 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +5.25%).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Healthcare · Medical Devices · 11,000 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Healthcare · Medical Devices · 1,178 employees
DXCM vs TXG FAQ
Which is bigger, DexCom or 10x Genomics?
DexCom (DXCM) is larger, with a market capitalization of $31.85B compared with $10.07B for 10x Genomics (TXG).
Which stock has performed better over the past year, DXCM or TXG?
TXG returned +540.27% over the past 12 months, compared with +24.54% for DXCM (price return, excluding dividends). Past performance does not predict future results.
Are DexCom and 10x Genomics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.